Cullinan Therapeutics Inc. Common Stock (CGEM)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Cullinan as a Graham-style analyst: what is proven, what is paid, and what cushion exists? The company is a clinical-stage biopharmaceutical firm with 109 employees, developing CD19xCD3 and BCMAxCD3 bispecific T-cell engagers in Phase 1. It reports no revenue in the filed figures, and losses have been persistent: net loss of $153.2 million in FY2023, $167.4 million in FY2024, and $219.9 million in FY2025. More recent quarters show no letup: a $53.7 million net loss in fiscal Q2 2026, the quarter ended 2026-06-30, and a $49.7 million net loss in fiscal Q1 2026, the quarter ended 2026-03-31. Free cash flow is negative $159.3 million over the trailing twelve months, a -17.6% FCF yield on the $907.4 million market cap. That is a business consuming capital, not producing it. The balance sheet shows low leverage with D/E of 0.01, and an Altman Z-Score of 11.29, but the Piotroski F-Score is 1/9, reflecting weak fundamental momentum. At the 2026-10-13 close of $14.10, FairStock calculates P/B of 2.82 and a negative P/E of -4.53, so earnings-based valuation is meaningless. The FairStock Score is 37/100. A moat is unproven; in biotech, the only durable advantage comes from successful trials, patents, and approvals, none of which are in the provided figures. The Lynch category is TURNAROUND, for a loss in the latest year after earlier profits, but the filed annual numbers show continuing losses. Growth is a pipeline promise, not an earned record. I would need far more evidence of clinical and financial progress before calling this a value opportunity.

In plain English: Cullinan Therapeutics is a small biotech company working on experimental medicines for autoimmune diseases and cancer. It has no reported revenue and is losing money while spending cash on early-stage human trials. At $14.10, the stock looks expensive compared with its current business numbers, so its value relies mostly on whether its drugs succeed in testing.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer